Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GWP42003 as Adjunctive Therapy in Schizophrenia
NCT02006628Phase 2Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Feb 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of cannabidiol in schizophrenia, schizoaffective disorder, schizophreniform disorder, sponsored by Jazz Pharmaceuticals plc. Started Feb 2014; status: completed.
02
Drugs
cannabidiol
03
Conditions
schizophreniaschizoaffective disorderschizophreniform disorder
Beyond the preview
Go deeper on NCT02006628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02006628.